drugset / Trial / NCT03203369
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.
Timeline
- Start
- 2017-06-28
- Primary completion
- 2019-06-27
- Completion
- 2019-06-27
Outcome
Outcome not reported
Stopped: “The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCART123 | Cell therapy | 625000 cells/kg | Intravenous |
| Subject | UCART123 | Cell therapy | 6.25e+06 cells/kg | Intravenous |